Home/Pipeline/BT7455

BT7455

Solid Tumors (targeting EphA2 & CD137)

PreclinicalActive

Key Facts

Indication
Solid Tumors (targeting EphA2 & CD137)
Phase
Preclinical
Status
Active
Company

About Bicycle Therapeutics

Bicycle Therapeutics aims to become a world-leading solid tumor medicines company by leveraging its proprietary Bicycle® platform to create precision-guided therapeutics. Its core technology enables the rapid discovery and development of constrained peptides with high affinity and selectivity for challenging targets. The company is progressing multiple clinical-stage oncology assets and has established creative collaborative relationships to expand its technology into anti-infective, cardiovascular, and CNS diseases.

View full company profile